Results 131 to 140 of about 46,913 (254)

Case Report: Exposure to Relapsing Fever Group Borreliae in Patients with Undifferentiated Febrile Illness in Mexico. [PDF]

Am J Trop Med Hyg, 2023
Vázquez-Guerrero E, Gordillo-Pérez G, Ríos-Sarabia N, Lopez JE, Ibarra JA.   +4 more
europepmc   +1 more source

Serological evidence of Borrelia turicatae in Raccoons (Procyon lotor) from an endemic focus of tick-borne relapsing fever in Mexico. [PDF]

PLoS Negl Trop Dis
Hernández Martínez JA, Leal-Sepúlveda V, Zavala-Norzagaray AA, Rendón-Franco E, Ley-Quiñonez CP, Pellegrini-Hernández P, Lopez JE, Ibarra JA.   +7 more
europepmc   +1 more source

Expression of Concern: Head Lice of Pygmies Reveal the Presence of Relapsing Fever Borreliae in the Republic of Congo. [PDF]

PLoS Negl Trop Dis, 2022
PLOS Neglected Tropical Diseases Editors.
europepmc   +1 more source

Melioidosis in companion animals: Analysis of 45 Australian cases (24 dogs; 21 cats) from 1997 to 2025 and a brief review of the animal and human literature

Australian Veterinary Journal, EarlyView.
Objective To report 45 cases of melioidosis in dogs and cats from northern Australia and analyse trends in epidemiology, clinical presentation, pathogenesis and response to treatment over a 27‐year period. Design Retrospective and prospective analysis of clinical records.
K Lee, C Shilton, S Benedict, M Krockenberger, M Mayo, BJ Currie, R Malik   +6 more
wiley   +1 more source

Genomic and structural analysis of major antigenic proteins' variability in the human relapsing fever spirochete <i>Borrelia persica</i>. [PDF]

Curr Res Microb Sci
Shwartz D, Nachum-Biala Y, Straubinger RK, Segev O, Levy A, Lopez JE, Baneth G.   +6 more
europepmc   +1 more source

Historical overview and update on relapsing fever group Borrelia in Latin America. [PDF]

Parasit Vectors, 2022
Faccini-Martínez ÁA, Silva-Ramos CR, Santodomingo AM, Ramírez-Hernández A, Costa FB, Labruna MB, Muñoz-Leal S.   +6 more
europepmc   +1 more source

MRD‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM

British Journal of Haematology, EarlyView.
In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti, Francesca Bacchiarri, Ludovica Pengue, Dania Tocci, Irene Attucci, Maria Livia del Giudice, Miriana Ruggieri, Alessandra Lombardo, Anna Marina Liberati, Veronica Candi, Vincenzo Sammartano, Alessandra Cartocci, Anna Sicuranza, Sara Galimberti, Alessandro Maria Vannucchi, Monica Bocchia   +24 more
wiley   +1 more source

Europe's contribution to the evaluation of the use of systemic antimicrobials in the treatment of periodontitis

Periodontology 2000, EarlyView., 2023
Abstract This narrative review celebrates Europe's contribution to the current knowledge on systemically administered antimicrobials in periodontal treatment. Periodontitis is the most frequent chronic noncommunicable human disease. It is caused by dysbiotic bacterial biofilms and is commonly treated with subgingival instrumentation.
David Herrera, Arie Jan van Winkelhoff, Paula Matesanz, Katalina Lauwens, Wim Teughels   +4 more
wiley   +1 more source

Unusual presentation of complicated relapsing fever with spontaneous hemoperitoneum mimicking surgical acute abdomen: a case report. [PDF]

Int J Emerg Med
Tesfay YG, Adera HK, Demissie ZG, Alemu DM, Mohammed MS, Hassen GW, Nuguse MK.   +6 more
europepmc   +1 more source

Tick borne relapsing fever - a systematic review and analysis of the literature. [PDF]

PLoS Negl Trop Dis, 2022
Jakab Á, Kahlig P, Kuenzli E, Neumayr A.   +3 more
europepmc   +1 more source